OpGen (NASDAQ:OPGN) Coverage Initiated at StockNews.com

Research analysts at StockNews.com assumed coverage on shares of OpGen (NASDAQ:OPGN) in a research note issued to investors on Tuesday. The firm set a “sell” rating on the medical research company’s stock.

OpGen Price Performance

OPGN stock opened at $2.24 on Tuesday. The company’s 50-day simple moving average is $2.69 and its 200-day simple moving average is $4.11. OpGen has a 52-week low of $1.65 and a 52-week high of $38.40.

OpGen (NASDAQ:OPGN) last posted its earnings results on Monday, July 8th. The medical research company reported $0.21 earnings per share (EPS) for the quarter. OpGen had a negative net margin of 997.34% and a negative return on equity of 1,827.76%. The business had revenue of $0.17 million for the quarter.

Institutional Investors Weigh In On OpGen

An institutional investor recently bought a new position in OpGen stock. Chase Investment Counsel Corp bought a new position in shares of OpGen, Inc. (NASDAQ:OPGN) during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 331,890 shares of the medical research company’s stock, valued at approximately $230,000. Chase Investment Counsel Corp owned approximately 2.63% of OpGen as of its most recent SEC filing. Institutional investors own 2.68% of the company’s stock.

OpGen Company Profile

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.